To investigate the relationship between the type 2 inflammatory response associated with asthma and lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV).
Methods:
Sixty-seven children with RSV infection hospitalized in our hospital from October 2023 to December 2023 and 27 healthy children undergoing medical examination were included. The study population was divided into the RSV LRTI group (n = 67) and the control group (n = 27). Interleukin-13 (IL-13), serum total immunoglobulin E (IgE), mucin 5AC (MUC5AC), and blood eosinophil count (EOS) were tested and compared between the two groups. The presence or absence of specificity between the two groups was analyzed using the rank sum test and subject operating characteristic curves (Receiver Operating Characteristic curves, ROC curves).
Results:
The levels of IL-13, IgE, MUC5AC, and EOS were higher in children with RSV LRTI compared to healthy children. These differences were statistically significant (P < .05). The ROC curve analysis results showed that IL-13, IgE, MUC5AC, and EOS predicted type 2 inflammation with areas under the curve of 0.687, 0.762, 0.764, and 0.646, respectively.
Conclusion:
A type 2 inflammatory response associated with asthma may be observed after RSV-induced LRTIs.
KubotaJHiranoDOkabeS, et al. Utility of the global respiratory severity score for predicting the need for respiratory support in infants with respiratory syncytial virus infection. PLoS ONE. 2021;16(7):e0253532. doi:10.1371/journal.pone.0253532.
BusseWWKraftMRabeKF, et al. Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. Eur Respir J. 2021;58(2):2003393. doi:10.1007/s40121-020-00390-7.
4.
RobinsonDHumbertMBuhlR, et al. Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017;47(2):161-175. doi:10.1111/cea.12880.
5.
SenPKhatriSBTejwaniV.Measuring exhaled nitric oxide when diagnosing and managing asthma. Cleve Clin J Med. 2023;90(6):363-370. doi:10.3949/ccjm.90a.22072131.
6.
YaoHSHanXH.Management of airway mucus hypersecretion in children. Chin J Pract Pediatr. 2021;36(3):178-184. doi:10.19538/j.ek2021030674.
7.
ZhangDYangJZhaoY, et al. RSV infection in neonatal mice induces pulmonary eosinophilia responsible for asthmatic reaction. Front Immunol. 2022;13:817113. doi:10.3389/fimmu.2022.817113.
8.
KosanovichJEichingerKLippM, et al. Exacerbated lung inflammation following secondary RSV exposure is CD4+ T cell-dependent and is not mitigated in infant BALB/c mice born to PreF-vaccinated dams. Front Immunol. 2023;14:1206026. doi:10.3389/fimmu.2023.1206026.
9.
VenkatesanP.2023 GINA report for asthma. Lancet Respir Med. 2023;11(7):589. doi:10.1016/S2213-2600(23)00230-8.
10.
HanPZhengYJShenKL.Progress in type 2 inflammation and biological therapy in children. Chin J Pract Pediatr Clin. 2023;38(11):801-805. doi:10.3760/cma.j.cn101070-20230831-00141.
11.
Chinese Society of Allergology. Expert consensus on the mechanisms and targeted treatment of type 2 inflammatory diseases. Chin Med J. 2022;102(42):3349-3373. doi:10.3760/cma.j.cn112137-20220628-01431.
12.
KolkhirPAkdisCAAkdisM, et al. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs. Nat Rev Drug Discov. 2023;22(9):743-767. doi:10.1038/s41573-023-00750-1.
13.
JunttilaIS.Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes. Front Immunol. 2018;9:888. doi:10.3389/fimmu.2018.00888.
14.
GandhiNABennettBLGrahamNMPirozziGStahlNYancopoulosGD.Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50. doi:10.1038/nrd4624.
15.
BonserLRErleDJ.Airway mucus and asthma: the role of MUC5AC and MUC5B. J Clin Med. 2017;6(12):112. doi:10.3390/jcm6120112.
16.
ZhangXCuiFXTangJQ, et al. Mechanisms and treatment progress of eosinophilic asthma. Int J Respir. 2023;43(4):476–480.
17.
MaJRubinBKVoynowJA.Mucins, mucus, and goblet cells. Chest. 2018;154(1):169-176. doi:10.1016/j.chest.2017.11.008.
18.
OkudaKChenGSubramaniDB, et al. Localization of secretory mucins MUC5AC and MUC5B in normal/healthy human airways. Am J Respir Crit Care Med. 2019;199(6):715-727. doi:10.1164/rccm.201804-0734OC.
19.
ChatterjeeMvan PuttenJPMStrijbisK.Defensive properties of mucin glycoproteins during respiratory infections-relevance for SARS-CoV-2. Mbio. 2020;11(6):e02374. doi:10.1128/mBio.02774-20.
20.
AkdisCAArkwrightPDBrüggenMC, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582-1605. doi:10.1111/all.14318.
21.
JarttiTBønnelykkeKEleniusV, et al. Role of viruses in asthma. Semin Immunopathol. 2020;42(1):61-74. doi:10.1007/s00281-020-00781-5.
22.
JarttiTGernJE.Role of viral infections in the development and exacerbation of asthma in children. J Allergy Clin Immunol. 2017;140(4):895-906. doi:10.1016/j.jaci.2017.08.003.
23.
NorlanderAEPeeblesRSJr.Innate type 2 responses to respiratory syncytial virus infection. Viruses. 2020;12(5):521. doi:10.3390/v12050521.
24.
HsuATGottschalkTATsantikosEHibbsML.The role of innate lymphoid cells in chronic respiratory diseases. Front Immunol. 2021;12:733324. doi:10.3389/fimmu.2021.733324.
25.
XueLSalimiMPanseI, et al. Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells. J Allergy Clin Immunol. 2014;133(4):1184-1194. doi:10.1016/j.jaci.2013.10.056.
26.
FonsecaWMalinczakCASchulerCF, et al. Uric acid pathway activation during respiratory virus infection promotes Th2 immune response via innate cytokine production and ILC2 accumulation. Mucosal Immunol. 2020;13(4):691-701. doi:10.1038/s41385-020-0264-z.
27.
HuPQJiaoJWangXDCaiCZhangL.Progress in the regulation of respiratory mucin MUC5AC expression. Int J Otolaryngol Head Neck Surg. 2021;45(4):215-218. doi:10.3767/cma.j.issn.1673-4106.2021.04.008.
28.
RajanDO’KeefeELTraversC, et al. MUC5AC levels associated with respiratory syncytial virus disease severity. Clin Infect Dis. 2018;67(9):1441-1444. doi:10.1093/cid/ciy340.
29.
CurrierMGLeeSStobartCC, et al. EGFR interacts with the fusion protein of respiratory syncytial virus strain 2-20 and mediates infection and mucin expression. PLoS Pathog. 2016;12(5):e1005622. doi:10.1371/journal.ppat.1005622.
30.
SugitaKSteerCAMartinez-GonzalezI, et al. Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients. J Allergy Clin Immunol. 2018;141(1):300-310. doi:10.1016/j.jaci.2017.02.038.
31.
MansonMLSäfholmJJamesA, et al. IL-13 and IL-4, but not IL-5 nor IL-17A, induce hyperresponsiveness in isolated human small airways. J Allergy Clin Immunol. 2020;145(3):808-817.e2. doi:10.1016/j.jaci.2019.10.037.
32.
JacksonNDEvermanJLChioccioliM, et al. Single-cell and population transcriptomics reveal pan-epithelial remodeling in type 2-high asthma. Cell Rep. 2020;2(1):107872. doi:10.1016/j.celrep.2020.107872.
33.
MukherjeeSLukacsNW.Association of IL-13 in respiratory syncytial virus-induced pulmonary disease: still a promising target. Expert Rev Anti Infect Ther. 2010;8(6):617-621. doi:10.1586/eri.10.39.
34.
KoppEBAgaronyanKLicona-LimónI, et al. Modes of type 2 immune response initiation. Immunity. 2023;56(4):687-694. doi:10.1016/j.immuni.2023.03.015.
35.
JacksonDJGernJE.Rhinovirus infections and their roles in asthma: etiology and exacerbations. J Allergy Clin Immunol Pract. 2022;10(3):673-681. doi:10.1016/j.jaip.2022.01.006.
36.
HasegawaKMansbachJMBochkovYA, et al. Association of rhinovirus C bronchiolitis and immunoglobulin E sensitization during infancy with development of recurrent wheeze. JAMA Pediatr. 2019;173(6):544-552. doi:10.1001/jamapediatrics.2019.0384.
37.
BasnetSBochkovYABrockman-SchneiderRA, et al. CDHR3 asthma-risk genotype affects susceptibility of airway epithelium to rhinovirus C infections. Am J Respir Cell Mol Biol. 2019;61(4):450-458. doi:10.1165/rcmb.2018-0220OC.
38.
MakriniotiHHasegawaKLakoumentasJ, et al. The role of respiratory syncytial virus- and rhinovirus-induced bronchiolitis in recurrent wheeze and asthma-a systematic review and meta-analysis. Pediatr Allergy Immunol. 2022;33(3):e13741. doi:10.1111/pai.13741.
39.
LiYWangXBlauDM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047-2064. doi:10.1016/S0140-6736(22)00478-0.
40.
ChenXLuoZXShenZB, et al. Expert consensus on the treatment of expectoration and cough in children. Chin J Pract Pediatr. 2022;08:567-574. doi:10.19538/j.ek2022080672.
41.
van MeelERMensink-BoutSMden DekkerHT, et al. Early-life respiratory tract infections and the risk of school-age lower lung function and asthma: a meta-analysis of 150,000 European children. Eur Respir J. 2022;60(4):2102395. doi:10.1183/13993003.02795-2021.
42.
HowellIHowellAPavordID.Type 2 inflammation and biological therapies in asthma: targeted medicine taking flight. J Exp Med. 2023;220(7):e20221212. doi:10.1084/jem.20221212.
43.
CorrenJSzeflerSJSherE, et al. Lebrikizumab in uncontrolled asthma: reanalysis in a well-defined type 2 population. J Allergy Clin Immunol Pract. 2024;12(5):1215-1224. doi:10.1016/j.jaip.2024.02.007.
